Case guide

UPDATED FEB 2026

Bard PowerPort MDL in the District of Arizona

Part of the Bard PowerPort Catheter investigation

The short answer

MDL No. 3:22-md-03062 in the U.S. District Court for the District of Arizona is the central federal forum for all Bard PowerPort catheter fracture cases. Understanding how the MDL works, where it currently stands, and what participation means for individual plaintiffs is essential for anyone considering a PowerPort lawsuit.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

What Is an MDL and How Does It Work?

A multidistrict litigation (MDL) is a federal procedural mechanism that consolidates related cases from courts across the country into a single district for coordinated pretrial proceedings. The Judicial Panel on Multidistrict Litigation (JPML) transfers cases sharing common factual questions to a single transferee court — in this case, the U.S. District Court for the District of Arizona — where one judge manages all pretrial matters for the entire litigation. The MDL does not merge the cases into a single lawsuit: each plaintiff retains their individual case, their individual claimed damages, and their individual right to a separate trial or settlement. The efficiency of the MDL comes from sharing discovery — documents, depositions of Becton Dickinson witnesses, and general causation expert work — across all cases rather than duplicating those efforts thousands of times.

The PowerPort MDL was established by JPML Order dated October 2022, consolidating cases pending in multiple federal districts. The MDL Judge issues Case Management Orders (CMOs) governing the schedule for plaintiff fact sheets, defendant document production, expert disclosure deadlines, and bellwether trial selection. The Plaintiffs' Steering Committee (PSC) — a group of experienced plaintiffs' attorneys appointed by the court — leads plaintiff-side discovery strategy on behalf of all plaintiffs. Individual plaintiffs' attorneys work with the PSC while maintaining their individual client relationships.

Where the MDL Stands as of Early 2026

As of early 2026, the Bard PowerPort MDL in the District of Arizona has grown to include thousands of plaintiffs with claims arising from catheter fracture, fragment embolization, infection, cardiac injury, and wrongful death. General causation discovery — addressing whether the PowerPort's polyurethane catheter is capable of fracturing and causing the injuries alleged — has proceeded with expert disclosures from both sides. Becton Dickinson has produced millions of pages of internal documents through the discovery process, including communications about the polyurethane degradation issue, adverse event reports submitted to the FDA under 21 CFR Part 803, and internal materials science testing data. The bellwether trial selection process, in which a pool of representative cases is selected for early trial to generate jury verdict data, is underway. Bellwether verdicts are expected to catalyze global settlement negotiations.

What Joining the MDL Means for Individual Plaintiffs

Filing a PowerPort claim means filing a complaint in any federal district court, which is then transferred to the District of Arizona MDL. Within the MDL, each plaintiff completes a Plaintiff Fact Sheet (PFS) — a detailed questionnaire documenting the device implantation date, medical history, fracture discovery, injuries sustained, and treatment received. The PFS serves as the primary individual case record during MDL proceedings. Plaintiffs do not attend hearings or appear in Arizona — their attorneys handle all court appearances. Individual plaintiffs receive updates from their attorneys as the MDL progresses through key milestones.

When the MDL reaches a global settlement, each plaintiff's claim is evaluated individually against a settlement compensation matrix that assigns values based on injury severity, age, and other factors. Plaintiffs are not required to accept a global settlement — each plaintiff has the right to opt out and proceed to individual trial. In practice, the overwhelming majority of MDL plaintiffs accept global settlements because they represent fair compensation without the delay and uncertainty of individual trial. Plaintiffs who do not join the MDL and instead pursue state court claims may proceed on a parallel track, though they do not benefit from the MDL's shared discovery resources.

Key data

Data & Statistics

3 SOURCED FIGURES

MDL No. 3:22-md-03062 — U.S. District Court for the District of Arizona

JPML Transfer Order, October 2022

MDL bellwether trials expected 2025-2026 based on standard MDL timeline progression

MDL Case Management Orders

Median time from MDL establishment to first global settlement: approximately 3-5 years (based on comparable device MDLs)

Duke Law Center for Judicial Studies, Mass Tort MDL Study

FAQ

Frequently Asked Questions

12 QUESTIONS

A Bard PowerPort is a brand of implantable venous access port (IVAP) made by C.R. Bard (now part of Becton Dickinson). It consists of a small reservoir implanted under the chest skin connected to a polyurethane catheter threaded into a large central vein near the heart. The device provides long-term intravenous access for chemotherapy, blood draws, and medication delivery without repeated needle sticks. Millions of patients have received PowerPort devices, with cancer patients being the primary recipients. The defect at the center of current litigation is the polyurethane catheter's susceptibility to fracturing inside the body over time.

Dive deeper

Related Guides

9 GUIDES

The full investigation

Part of the Bard PowerPort Catheter Investigation